Evidence map›Paper›PMID 40155594›Full record

ArticleNature communications2025

Muscle-specific Ryanodine receptor 1 properties underlie limb-girdle muscular dystrophy 2B/R2 progression.

Aldo Meizoso-Huesca, Cedric R Lamboley, James R Krycer, Mark P Hodson, James E Hudson, Bradley S Launikonis

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. An Unbiased Drug Screen in a Drosophila Model ofInternational journal of molecular sciences · 2026
    Article
  2. iPLAScience advances · 2026
    Article
  3. Review
  4. Review
  5. The two faces of mitochondrial CaJournal of physiology and biochemistry · 2026
    Review
  6. Ryanodine Receptor CaActa physiologica (Oxford, England) · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Phosphorylation of RYR1 at SerScience signaling · 2025
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aldo Meizoso-HuescaSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0001-7873-5398
Cedric R LamboleySchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.
James R KrycerQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Mark P HodsonQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0002-5436-1886
James E HudsonSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.ORCID http://orcid.org/0000-0003-0832-9356
Bradley S LaunikonisSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia. b.launikonis@uq.edu.au.ORCID http://orcid.org/0000-0003-0700-4867

Funding

Department of Education and Training | Australian Research Council (ARC) DP220102018
6 · The paper itself

Abstract

Ryanodine receptor 1 Ca

Indexed as

Muscle, SkeletalMuscular Dystrophies, Limb-GirdleRyanodine Receptor Calcium Release ChannelAnimalsCalciumDisease Models, AnimalDisease ProgressionDysferlinMaleMiceMice, Inbred C57BLMice, KnockoutPhosphorylationReactive Oxygen SpeciesCalciumDysferlinDysf protein, mouseReactive Oxygen Speciesryanodine receptor 1, mouseRyanodine Receptor Calcium Release Channel

Identifiers

PMID40155594
PMCPMC11953303

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.